BXRX =MC $60 M --Cash $20 -- NDA (Class 1) resubmission for IV Meloxicam with approval likely in March or April =500%+ GEM https://www.sec.gov/Archives/edgar/data/1780097/000119312519306813/g841356ex99_1s7g1.jpg